News About: Pharm. Industry
A shift in generations of periodontal disease treatment market is becoming clearer
A shift in generations of periodontal disease treatment market is becoming clearer.
According to the recent scores of periodontal disease treatment over the past five years (IMS DATA), 'Insadol' from Dongkook Pharmac...
Blockbuster natural drug Stillen's incrementally modified drugs are showing steady increase in sales
Blockbuster natural drug Stillen's incrementally modified drugs are showing steady increase in sales after launching.
Among the Stillen's incrementally modified drugs, 'Nexilen' of Jeil Pharmaceutical recorded the hi...
Multinational pharmaceutical companies changed their attitude on blockbuster whose patents have expired
Multinational pharmaceutical companies changed their attitude on blockbuster whose patents have expired. In the old days, they used to cut the marketing budget and stopped investment on research. However, they are now...
The acquisition of DreamPharma seems to be turning into a three-way battle of Kwangdong Pharmaceutical, Ahngook Pharmaceutical and Alvogen
The acquisition of DreamPharma seems to be turning into a three-way battle of Kwangdong Pharmaceutical, Ahngook Pharmaceutical and Alvogen.
On May 20, the headquarter of stock market asked companies including JW Joon...
It turned out that ratio of cost of sales of domestic pharmaceutical company was lower than that of multinational pharmaceutical company
According to the 2013 Public Announcement of domestic top 10 pharmaceutical companies in sales and top 10 multinational pharmaceutical companies in sales which is submitted to Financial Supervisory Service, it turned ...
Pfizer Korea recently launched calcium supplement 'Caltrate plus-D500'
Pfizer Korea recently launched calcium supplement 'Caltrate plus-D500', followed by painkillers 'Advil' which was launched in last year. Both items are recording no.1 in sales in the world, so they are considered as a...
71 listed pharmaceutical companies invested 800.1 billion won in R & D last year
It was analyzed that 71 listed pharmaceutical companies invested 800.1 billion won in R & D last year. This amount is an increase of 13.1% year-over-year.
These R & D to sales ratio is 7.2%, which is increased by 0.2...
GSK 'Avandia' which disappeared from the market with the reason of cardiovascular safety controversy in 2011, will soon be re-released
Medical community is expecting that GSK 'Avandia' which disappeared from the market with the reason of cardiovascular safety controversy in 2011, will soon be re-released. Because last November which is 2 year after t...
SK Chemical announced that they won a suit of banning infringement of the patent against Novartis
On May 15, SK Chemical announced that they won a suit of banning infringement of the patent against Novartis.
The lawsuit is about 'Rivastigmine' which has efficacy in treatment of dementia, and
'Exelon patch' which...
Domestic new drugs get weak-kneed in the aspect of sales
According to the policy report published by the Korea Pharmaceutical Manufacturers Association, currently there are a total of 20 domestic new drug, and the total sales of these drugs in 2013 is 73.8 billion won. Cons...
